Biotech · Public company · New York, NY, US

Brainstorm Cell Therapeutics Inc.

Ticker BCLI · SEC CIK 0001137883

Track this companyFree. Adds Brainstorm Cell Therapeutics Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials51 recruiting or active

Pipeline programs5From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline5

Bone Marrow aspirationPhase 3 · Amyotrophic Lateral Sclerosis (ALS)ClinicalTrials.gov · fetched Nov 12, 2026
Debamestrocel - MSC-NTF (NurOwn)Phase 3 · Amyotrophic Lateral Sclerosis (ALS)ClinicalTrials.gov · fetched Nov 12, 2026
NurOwn® (MSC-NTF cells)Phase 3 · Amyotrophic Lateral Sclerosis (ALS)ClinicalTrials.gov · fetched Nov 12, 2026
NurOwn (MSC-NTF cells)Phase 2 · Multiple Sclerosis, Chronic ProgressiveClinicalTrials.gov · fetched Nov 12, 2026
NurOwn (MSC-NTF cells)Amyotrophic Lateral SclerosisClinicalTrials.gov · fetched Nov 12, 2026

Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)PHASE3 · NOT_YET_RECRUITING · started Jun 30, 2025ClinicalTrials.gov NCT06973629 · fetched Nov 12, 2026
Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MSPHASE2 · COMPLETED · started Mar 13, 2019ClinicalTrials.gov NCT03799718 · fetched Nov 12, 2026
Safety and Efficacy of Repeated Administrations of NurOwn® in ALS PatientsPHASE3 · COMPLETED · started Aug 28, 2017ClinicalTrials.gov NCT03280056 · fetched Nov 12, 2026
Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALSPHASE2 · COMPLETED · started May 1, 2014ClinicalTrials.gov NCT02017912 · fetched Nov 12, 2026
Expanded Access Protocol: Repeated Administration of Nurown® (Autologous MSC-NTF Cells) for the Treatment of ALSNO_LONGER_AVAILABLEClinicalTrials.gov NCT04681118 · fetched Nov 12, 2026